You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES

HIGHLIGHTS

CORPORATE

Kedrion Biopharma runner up at the Premio Equita for the bond issued in July 2017

The prize is awarded to the companies that made the best use of the capital markets

read more 

CORPORATE

Kedrion Biopharma joins Columbia University to celebrate 50 years of Anti-D

Since 1968, billions of babies have been saved from Hemolytic Disease of the Fetus and Newborn

read more 

CORPORATE

Hemophilia: Kedrion signs on to groundbreaking PARTNERS programme

Goal is to improve access to replacement therapies for coagulation disorders in Europe

read more 
  1. CORPORATE - 20-05-2014

    Kedrion, one of Italy’s most innovative companies in 2014

    The MIT Technology Review Italia’s award given in Bologna in mid-May

    read more 
  2. CORPORATE - 17-04-2014

    5-year unrated EUR 300 million bond successfully launched

    The bonds have been placed with leading international institutional investors and will be listed on the Irish Stock Exchange

    read more 
  3. CORPORATE - 16-04-2014

    Kedrion Group approves 2013 financial statements

    Achieved results of 425 million euros turnover and a 25% profitability

    read more 
  4. PLASMA & BIOTHERAPIES - 14-04-2014

    Kedrion collection centers first to be certified in Hungary

    Plazmaferezis Állomás Kft achieves international PPTA certification

    read more 

Pages

For more information please contact: pressoffice@kedrion.com